Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Advances in Epidermal Growth Factor Receptor-Driven Non-Small-Cell Lung Cancer: Diagnostic...
share announcement

Advances in Epidermal Growth Factor Receptor-Driven Non-Small-Cell Lung Cancer: Diagnostic Technologies and Therapeutic Strategies

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Causes, Screening and Diagnosis".

Deadline for manuscript submissions: 15 March 2025 | Viewed by 3038

Special Issue Editor

Dr. Fang Wei

E-Mail Website
Guest Editor
School of Dentistry, University of California, Los Angeles, CA, 90095, USA
Interests: liquid biopsy; NSCLC; point-of-care device; circulating tumor DNA; EFIRM platform
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are excited to announce a call for papers for a forthcoming Special Issue of our journal dedicated to diagnostic advances in epidermal growth factor receptor-targeted therapy for non-small-cell lung cancer. This Special Issue aims to spotlight the latest scientific research and advancements in the diagnosis and treatment of NSCLC, with a particular focus on the role of epidermal growth factor receptor (EGFR) targeting. 

We welcome submissions of original research papers and comprehensive review articles that contribute to, but are not limited to, the following areas:

  1. Technology/Device Advancement in Diagnosis: Innovations in diagnostic technologies or devices that enhance the detection and understanding of NSCLC, especially those that facilitate EGFR-targeted therapy approaches.
  2. Fundamental Biological Discovery: Breakthrough discoveries in the fundamental biology of NSCLC that significantly improve the diagnostic process. Submissions should focus on insights that pave the way for more effective EGFR-targeted diagnosis.
  3. Clinical Practice/Procedure to Assist Diagnosis: Papers that explore new clinical practices or procedures that aid in the timely and accurate diagnosis of NSCLC, thereby facilitating better patient outcomes through EGFR-targeted therapies.
  4. Combination of Diagnosis and Therapeutics: Research that examines the integration of diagnostic processes with therapeutic strategies to enhance the overall treatment outcome for NSCLC patients, including the role of EGFR targeting in treatment plans.
  5. Computer- or AI-Assisted Diagnosis: Submissions that highlight the application of computer science or artificial intelligence in diagnosing NSCLC, particularly in improving the precision of EGFR-targeted therapy decisions.

This Special Issue aims to cover a broad spectrum of NSCLC stages, including early-stage cancer, advanced-stage cancer, and the monitoring of NSCLC throughout therapeutic treatment. We believe that the comprehensive understanding and innovative approaches presented in this Special Issue will significantly contribute to the advancement of NSCLC diagnosis and treatment, ultimately improving patient care and outcomes. 

Submission Guidelines:

  • All submissions must be original work and not under consideration by other publications. 
  • Articles should adhere to the journal's submission guidelines, available on our website. 
  • Please indicate in your cover letter that your submission is for the special issue on "Advances in Epidermal Growth Factor Receptor-Driven Non-Small-Cell Lung Cancer: Diagnostic Technologies and Therapeutic Strategies”. 

We look forward to receiving your contributions and advancing the field of NSCLC diagnosis and treatment together. For any inquiries, please contact the Special Issue editors. 

Sincerely,

Dr. Fang Wei
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • EGFR-targeted therapy
  • non-small-cell lung cancer diagnosis
  • diagnostic technologies and devices
  • biological discoveries in NSCLC
  • AI-assisted diagnosis in oncology
  • clinical practice in NSCLC detection
  • therapeutic–diagnostic integration
  • early-stage lung cancer monitoring
  • advanced NSCLC diagnostic approaches
  • precision medicine in lung cancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 1136 KiB  
Article
Post-Progression Analysis of EGFR-Mutant NSCLC Following Osimertinib Therapy in Real-World Settings
by Ilaria Attili, Carla Corvaja, Gianluca Spitaleri, Pamela Trillo Aliaga, Ester Del Signore, Antonio Passaro and Filippo de Marinis
Cancers 2024, 16(14), 2589; https://doi.org/10.3390/cancers16142589 - 19 Jul 2024
Cited by 4 | Viewed by 1613
Abstract
Background: Platinum-based chemotherapy is the current standard treatment option in patients with EGFR-mutant non-small-cell lung cancer (NSCLC) who progress on osimertinib. However, outcomes with chemotherapy are dismal, and the treatment of central nervous system (CNS) disease is an unmet need in this [...] Read more.
Background: Platinum-based chemotherapy is the current standard treatment option in patients with EGFR-mutant non-small-cell lung cancer (NSCLC) who progress on osimertinib. However, outcomes with chemotherapy are dismal, and the treatment of central nervous system (CNS) disease is an unmet need in this setting. Methods: Patients with EGFR-mutant NSCLC who were candidates to receive osimertinib in the metastatic setting at our Center from 2015 to 2022 were retrospectively evaluated to identify patients who received standard platinum-based chemotherapy post-osimertinib. Data were collected on treatment outcomes, with a focus on brain metastases and progression patterns. Results: A total of 220 patients received indication for osimertinib in the study period; n = 176 had adequate follow-up data. Overall, n = 117 patients experienced disease progression on osimertinib. The median time to osimertinib progressive disease (PD) was 15 months (95% confidence interval CI 13–18). Of them, 51 patients (45%) had no access to further treatments. Of the remaining patients, n = 8 received experimental treatments, and n = 55 received standard platinum-based chemotherapy and were considered for this study. Median duration of chemotherapy was 3 months (95% CI 2–5); the best responses among 53 evaluable patients were observed as follows: 15% partial response/complete response (PR/CR), 40% stable disease (SD), 45% PD. Median progression-free survival (PFS) and overall survival (OS) were 3 (95% CI 2–5) and 10 (95% CI 6–15) months, respectively. All patients had baseline and follow-up brain radiologic assessments, and n = 23 had brain metastases at the start of chemotherapy. With a median follow-up of 13 months, intracranial PD occurred in 47% patients, being the first site of PD in 59% of cases. The median time for intracranial (IC) PD was 2 months (95% CI 2–7). IC PD occurred as oligometastatic in 29%, whereas in 71% of cases, it was associated with systemic PD. Conclusions: Access to subsequent treatments and CNS progression are confirmed unmet needs in EGFR-mutant NSCLC patients. Clinical and CNS-specific outcomes in patients receiving standard chemotherapy after the failure of osimertinib are dismal. Novel upfront treatment options with demonstrated prolonged PFS and better CNS outcomes may help address this important issue. Full article
(This article belongs to the Special Issue Advances in Epidermal Growth Factor Receptor-Driven Non-Small-Cell Lung Cancer: Diagnostic Technologies and Therapeutic Strategies)
►▼ Show Figures

Figure 1

Review

Jump to: Research

18 pages, 612 KiB  
Review
Osimertinib in the Treatment of Epidermal Growth Factor Receptor-Mutant Early and Locally Advanced Stages of Non-Small-Cell Lung Cancer: Current Evidence and Future Perspectives
by Antonello Veccia, Mariachiara Dipasquale, Martina Lorenzi, Sara Monteverdi, Stefania Kinspergher, Elena Zambotti and Orazio Caffo
Cancers 2025, 17(4), 668; https://doi.org/10.3390/cancers17040668 - 16 Feb 2025
Viewed by 353
Abstract
The treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) patients was dramatically revolutionized by the introduction of EGFR tyrosine kinase inhibitors in clinical practice, both in advanced and locally advanced/early stages. The present work focuses on osimertinib use in locally [...] Read more.
The treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) patients was dramatically revolutionized by the introduction of EGFR tyrosine kinase inhibitors in clinical practice, both in advanced and locally advanced/early stages. The present work focuses on osimertinib use in locally advanced and early NSCLC stages. Phase 3 clinical trials have supported the use of osimertinib as the new standard of care, both in the adjuvant setting and in locally advanced disease. The ADAURA study reported an overall survival (OS) advantage for adjuvant osimertinib in completely resected stage II-IIIA EGFR-mutant tumors, while the LAURA study proved a statistically significant benefit in progression-free survival (PFS) and a delay of central nervous system metastasis development in EGFR-mutant patients treated with osimertinib maintenance after concurrent chemoradiotherapy for locally advanced disease. In the neoadjuvant setting, data on osimertinib’s efficacy are conflicting; therefore, the Neo-ADAURA study is evaluating the efficacy and safety of neoadjuvant osimertinib alone or in combination with chemotherapy in patients with stage II-IIIB NSCLC and common EGFR mutations. We discuss several issues that need to be clarified, such as the efficacy of the drug on uncommon mutations, the long-term impact on survival, and the management of resistance mechanisms. Moreover, we report the studies that are trying to identify potential biomarkers of response, such as the circulating tumor DNA (ctDNA), with the aim of selecting patients who will benefit most from osimertinib. Full article
(This article belongs to the Special Issue Advances in Epidermal Growth Factor Receptor-Driven Non-Small-Cell Lung Cancer: Diagnostic Technologies and Therapeutic Strategies)
►▼ Show Figures

Figure 1

20 pages, 939 KiB  
Review
Possibilities of Overcoming Resistance to Osimertinib in NSCLC Patients with Mutations in the EGFR Gene
by Marcin Nicoś, Anna Sroka-Bartnicka, Ewa Kalinka and Paweł Krawczyk
Cancers 2025, 17(4), 563; https://doi.org/10.3390/cancers17040563 - 7 Feb 2025
Viewed by 546
Abstract
The advancement of genetic research has changed the treatment management of non-small cell lung cancer (NSCLC) and opened the era of personalized medicine. Currently, three generations of EGFR tyrosine kinase inhibitors (TKIs) are used in the treatment of NSCLC patients with activating mutations [...] Read more.
The advancement of genetic research has changed the treatment management of non-small cell lung cancer (NSCLC) and opened the era of personalized medicine. Currently, three generations of EGFR tyrosine kinase inhibitors (TKIs) are used in the treatment of NSCLC patients with activating mutations in the EGFR gene, and ongoing clinical trials examine the safety and effectiveness of new third and fourth generations. Osimertinib, a third generation of TKIs that binds irreversibly to abnormal tyrosine kinase, may be applied in various indications in patients with NSCLC: (i) in the second and subsequent lines of therapy in patients with resistance to first-generation or second-generation EGFR TKIs, (ii) in the first line of treatment in monotherapy in NSCLC patients with frequent or rare EGFR mutations, (iii) in combination with chemotherapy in patients with locally advanced or metastatic NSCLC with frequent EGFR mutations, (iv) in consolidation therapy in patients with locally advanced NSCLC who had previously received chemoradiotherapy, (v) in adjuvant treatment of NSCLC patients with stage IB—IIIA undergoing radical surgical resection. Despite the high efficacy of osimertinib in NSCLC patients harboring EGFR mutations, resistance driven in EGFR-dependent or EGFR-independent mechanisms may occur. Since resistance to osimertinib is poorly understood, the following review presents the overview of resistance mechanisms to osimertinib, methodological approaches for the resistance diagnosis, and the up-to-date treatment possibilities for overcoming the resistance process. Full article
(This article belongs to the Special Issue Advances in Epidermal Growth Factor Receptor-Driven Non-Small-Cell Lung Cancer: Diagnostic Technologies and Therapeutic Strategies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop